Neurotrope Inc. (NASDAQ: NTRP)is announcing a collaboration with The Nemours / Alfred I. duPont Hospital for Children ("Nemours") to initiate a clinical trial in children with Fragile X Syndrome ("Fragile X").
Pieris Pharmaceuticals, Inc.(NASDAQ: PIRS) announced today that it has dosed the first patient in the Company’s Phase 1 combination clinical trial of its lead proprietary immuno-oncology drug.
